cultivate(MD) portfolio company Strados Labs, the respiratory endpoint intelligence company, announced the acquisition of NuvoAir Clinical Trials from NuvoAir Inc.
The transaction, which closed in March 2026, expands Strados’ suite of solutions to include remote and in-clinic spirometry, FeNO measurement, and electronic clinical outcome assessment (eCOA) — complementing its existing technologies for cough monitoring and lung sound monitoring to create a unique end-to-end offering for Phase I through Phase IV respiratory trials.
The acquisition brings together the gold standard for continuous ambulatory cough monitoring and lung sound analysis with proven remote spirometry and FeNO capabilities — creating a unique, single-partner endpoint solution for respiratory sponsors.
With the integration of NuvoAir’s clinical trial capabilities, the Strados Endpoint Suite now combines:
- The RESP® Biosensor and RESP® Watch for continuous cough monitoring and lung sound analysis
- Strados spirometry for remote and in-clinic pulmonary function testing
- Strados FeNO for airway inflammation measurement
- Strados eCOA for patient-reported and clinician-reported respiratory outcomes
- Pharmaceutical and biotech sponsors and their CRO partners working across respiratory and pulmonary indications — including COPD, asthma, and chronic cough — can access every endpoint their program requires from a single partner, with one integration and no handoff risk across modalities.
“Respiratory drug development increasingly depends on capturing what happens between clinic visits, not just during them. By bringing these capabilities together under the Strados Endpoint Suite, we’re giving sponsors a single solution to collect the continuous and structured respiratory data they need — with data quality and regulatory credibility built in at the point of measurement.”
— Nick Delmonico, CEO and Co-Founder, Strados Labs
